Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 19Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 3Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Pathologic Complete Response 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, T-Cell, Peripheral 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Cytarabine 3Thioguanine 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Idarubicin 2Hydrocortisone 2Filgrastim 2Etoposide 2Daunorubicin 2Asparaginase 2palmitoyl-L-asparaginase 1merphos 1hydrocortisone hemisuccinate 1fludarabine phosphate 1aldesleukin 1Transplantation 1Radiotherapy, Conformal 1Interleukin-2 1Granulocyte Colony-Stimulating Factor 1Dexamethasone 1Decitabine 1Cyclophosphamide 1Calcium Dobesilate 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Anemia, Refractory × Decitabine × Clear all
NCT00043134 2010-04-13

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 3 Unknown
220 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡